|Status|| ‒ US Launched in November 2016 by Par Pharmaceutical.
‒ Canada Launched by a commercialization partner of Handa.
|Product Advantages|| ‒ First- to File, 180-day market exclusivity right in the USA.
‒ Final approval for 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg.
|Market Size||Handa has received profit sharing of more than $20 million in the USA and more than $3.5 million in Canada.|